| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q3'26 | August 6, 2026 | 4/12 | 1 high, 2 medium, 2 low flags | 0 | 0 | Call sheet → |
| Q2'26 | May 7, 2026 | 9/12 | 1 high, 3 medium, 3 low flags | 3 | 0 | Call sheet → |
| Q1'26 | February 9, 2026 | 11/12 | 3 medium, 4 low flags | 6 | 0 | Call sheet → |
| Q4'25 | November 6, 2025 | 10/12 | 1 medium, 5 low flags | 5 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Delivered | Alaris share gains momentum 150 basis points YTD share gains, largest competitive funnel ever |
| Q2'26 | Delivered | Double-digit growth in key growth platforms APM, biologics, PureWick, ATR all delivered double-digit growth |
| Q2'26 | Exceeded | $200 million cost-out program completion Already at $150M run rate, ahead of schedule |
| Q2'26 | Pending | Revenue growth in second half roughly similar to first half New guidance suggesting no acceleration expected |
| Q2'26 | Pending | Adjusted operating margin of about 25% Q2 at 24.2%, tracking toward full-year target |
| Q2'26 | Pending | Low single-digit revenue growth for New BD in fiscal 2026 Reaffirmed guidance, Q2 at 2.6% within range |
| Q1'26 | Delivered | Mid-single-digit growth in 90% of portfolio excluding headwinds New BD grew 2.5% with headwinds isolated to known 10% of business as promised. |
| Q1'26 | Delivered | Continued BD Excellence productivity momentum Sustained 8% productivity improvements, now expanding into commercial and R&D organizations. |
| Q1'26 | Delivered | Free cash flow conversion improvement Q1 conversion improved to 66% vs 59% prior year, working capital discipline showing results. |
| Q1'26 | Exceeded | Waters transaction to close around end of Q1 calendar 2026 Closed two months early, demonstrating strong execution and partnership. |
| Q1'26 | Delivered | Continue strong momentum in APM into FY26 High single-digit growth with 15% sales force expansion underway, tracking ahead of deal model. |
| Q1'26 | Delivered | Record $25 billion revenue and record 25% operating margin for FY25 Hit exactly on both metrics despite tariff headwinds. Strong execution. |
| Q4'25 | Delivered | Mid-single-digit growth in Surgery driven by tissue regeneration Surgery delivered mid-single digits with double-digit growth in advanced tissue regeneration |
| Q4'25 | Pending | Waters transaction closing around end of Q1 calendar 2026 Received FTC clearance, on track for timeline |
| Q4'25 | Exceeded | Complete $1B share buyback by end of September Completed ahead of schedule, announced additional $250M for Q1 |
| Q4'25 | Delivered | Deliver 25% operating margin by 2025 Hit exactly 25% for full year despite 40 bps tariff headwind |
| Q4'25 | Delivered | Continue momentum in BACTEC utilization recovery BACTEC exceeded 85% of historical levels vs 80% in Q3 |
| Q4'25 | Delivered | Expect year-over-year organic growth to improve sequentially in Q4 New BD grew 4.9% in Q4 vs 4% in Q3, 90 bps acceleration delivered |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.